Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors [Corrigendum]
Wu H, Infante JR, Keedy VL, et al. Int J Nanomedicine. 2015:10;1201—1209 On page 1208, Disclosure section, “The authors report no conflicts of interest in the work” has been updated since publication. Read the original article
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2019-07-01
|
| Series: | International Journal of Nanomedicine |
| Online Access: | https://www.dovepress.com/httpswwwdovepresscomcorrigendum-factors-affecting-the-pharm-peer-reviewed-article-IJN |
| id |
doaj-f7e040c8333d42af9a814346b023d546 |
|---|---|
| record_format |
Article |
| spelling |
doaj-f7e040c8333d42af9a814346b023d5462020-11-24T23:54:37ZengDove Medical PressInternational Journal of Nanomedicine1178-20132019-07-01Volume 145751575247395Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors [Corrigendum]Wu HInfante JRKeedy VLJones SFChan EBendell JCLee WKirschbrown WPZamboni BAIkeda SKodaira HRothenberg MLBurris III HAZamboni WCWu H, Infante JR, Keedy VL, et al. Int J Nanomedicine. 2015:10;1201—1209 On page 1208, Disclosure section, “The authors report no conflicts of interest in the work” has been updated since publication. Read the original articlehttps://www.dovepress.com/httpswwwdovepresscomcorrigendum-factors-affecting-the-pharm-peer-reviewed-article-IJN |
| collection |
DOAJ |
| language |
English |
| format |
Article |
| sources |
DOAJ |
| author |
Wu H Infante JR Keedy VL Jones SF Chan E Bendell JC Lee W Kirschbrown WP Zamboni BA Ikeda S Kodaira H Rothenberg ML Burris III HA Zamboni WC |
| spellingShingle |
Wu H Infante JR Keedy VL Jones SF Chan E Bendell JC Lee W Kirschbrown WP Zamboni BA Ikeda S Kodaira H Rothenberg ML Burris III HA Zamboni WC Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors [Corrigendum] International Journal of Nanomedicine |
| author_facet |
Wu H Infante JR Keedy VL Jones SF Chan E Bendell JC Lee W Kirschbrown WP Zamboni BA Ikeda S Kodaira H Rothenberg ML Burris III HA Zamboni WC |
| author_sort |
Wu H |
| title |
Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors [Corrigendum] |
| title_short |
Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors [Corrigendum] |
| title_full |
Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors [Corrigendum] |
| title_fullStr |
Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors [Corrigendum] |
| title_full_unstemmed |
Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors [Corrigendum] |
| title_sort |
factors affecting the pharmacokinetics and pharmacodynamics of pegylated liposomal irinotecan (ihl-305) in patients with advanced solid tumors [corrigendum] |
| publisher |
Dove Medical Press |
| series |
International Journal of Nanomedicine |
| issn |
1178-2013 |
| publishDate |
2019-07-01 |
| description |
Wu H, Infante JR, Keedy VL, et al. Int J Nanomedicine. 2015:10;1201—1209 On page 1208, Disclosure section, “The authors report no conflicts of interest in the work” has been updated since publication. Read the original article |
| url |
https://www.dovepress.com/httpswwwdovepresscomcorrigendum-factors-affecting-the-pharm-peer-reviewed-article-IJN |
| work_keys_str_mv |
AT wuh factorsaffectingthepharmacokineticsandpharmacodynamicsofpegylatedliposomalirinotecanihl305inpatientswithadvancedsolidtumorscorrigendum AT infantejr factorsaffectingthepharmacokineticsandpharmacodynamicsofpegylatedliposomalirinotecanihl305inpatientswithadvancedsolidtumorscorrigendum AT keedyvl factorsaffectingthepharmacokineticsandpharmacodynamicsofpegylatedliposomalirinotecanihl305inpatientswithadvancedsolidtumorscorrigendum AT jonessf factorsaffectingthepharmacokineticsandpharmacodynamicsofpegylatedliposomalirinotecanihl305inpatientswithadvancedsolidtumorscorrigendum AT chane factorsaffectingthepharmacokineticsandpharmacodynamicsofpegylatedliposomalirinotecanihl305inpatientswithadvancedsolidtumorscorrigendum AT bendelljc factorsaffectingthepharmacokineticsandpharmacodynamicsofpegylatedliposomalirinotecanihl305inpatientswithadvancedsolidtumorscorrigendum AT leew factorsaffectingthepharmacokineticsandpharmacodynamicsofpegylatedliposomalirinotecanihl305inpatientswithadvancedsolidtumorscorrigendum AT kirschbrownwp factorsaffectingthepharmacokineticsandpharmacodynamicsofpegylatedliposomalirinotecanihl305inpatientswithadvancedsolidtumorscorrigendum AT zamboniba factorsaffectingthepharmacokineticsandpharmacodynamicsofpegylatedliposomalirinotecanihl305inpatientswithadvancedsolidtumorscorrigendum AT ikedas factorsaffectingthepharmacokineticsandpharmacodynamicsofpegylatedliposomalirinotecanihl305inpatientswithadvancedsolidtumorscorrigendum AT kodairah factorsaffectingthepharmacokineticsandpharmacodynamicsofpegylatedliposomalirinotecanihl305inpatientswithadvancedsolidtumorscorrigendum AT rothenbergml factorsaffectingthepharmacokineticsandpharmacodynamicsofpegylatedliposomalirinotecanihl305inpatientswithadvancedsolidtumorscorrigendum AT burrisiiiha factorsaffectingthepharmacokineticsandpharmacodynamicsofpegylatedliposomalirinotecanihl305inpatientswithadvancedsolidtumorscorrigendum AT zamboniwc factorsaffectingthepharmacokineticsandpharmacodynamicsofpegylatedliposomalirinotecanihl305inpatientswithadvancedsolidtumorscorrigendum |
| _version_ |
1725465668981096448 |